亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial

医学 氟尿嘧啶 奥沙利铂 养生 全直肠系膜切除术 放化疗 外科 结直肠癌 内科学 化疗方案 化疗 放射治疗 临床终点 随机对照试验 癌症
作者
Claus Rödel,Ullrich Graeven,Rainer Fietkau,Werner Hohenberger,Torsten Hothorn,Dirk Arnold,Ralf‐Dieter Hofheinz,Michael Ghadimi,Richard Viebahn,Marga Lang-Welzenbach,Hans-Rudolf Raab,Christian Wittekind,Philipp Ströbel,Ludger Staib,Martin Wilhelm,Gerhard G. Grabenbauer,H.W. Hoffmanns,Fritz Lindemann,Anke Schlenska‐Lange,Gunnar Folprecht,Rolf Sauer,Torsten Liersch
出处
期刊:Lancet Oncology [Elsevier]
卷期号:16 (8): 979-989 被引量:625
标识
DOI:10.1016/s1470-2045(15)00159-x
摘要

Preoperative chemoradiotherapy with infusional fluorouracil, total mesorectal excision surgery, and postoperative chemotherapy with fluorouracil was established by the German CAO/ARO/AIO-94 trial as a standard combined modality treatment for locally advanced rectal cancer. Here we compare the previously established regimen with an investigational regimen in which oxaliplatin was added to both preoperative chemoradiotherapy and postoperative chemotherapy.In this multicentre, open-label, randomised, phase 3 study we randomly assigned patients with rectal adenocarcinoma, clinically staged as cT3-4 or any node-positive disease, to two groups: a control group receiving standard fluorouracil-based combined modality treatment, consisting of preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (1000 mg/m(2) on days 1-5 and 29-33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m(2) on days 1-5 and 29); or to an investigational group receiving preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (250 mg/m(2) on days 1-14 and 22-35) and oxaliplatin (50 mg/m(2) on days 1, 8, 22, and 29), followed by surgery and eight cycles of oxaliplatin (100 mg/m(2) on days 1 and 15), leucovorin (400 mg/m(2) on days 1 and 15), and infusional fluorouracil (2400 mg/m(2) on days 1-2 and 15-16). Randomisation was done with computer-generated block-randomisation codes stratified by centre, clinical T category (cT1-3 vs cT4), and clinical N category (cN0 vs cN1-2) without masking. The primary endpoint was disease-free survival, defined as the time between randomisation and non-radical surgery of the primary tumour (R2 resection), locoregional recurrence after R0/1 resection, metastatic disease or progression, or death from any cause, whichever occurred first. Survival and cumulative incidence of recurrence analyses followed the intention-to-treat principle; toxicity analyses included all patients treated. Enrolment of patients in this trial is completed and follow-up is ongoing. This study is registered with ClinicalTrials.gov, number NCT00349076.Of the 1265 patients initially enrolled, 1236 were assessable (613 in the investigational group and 623 in the control group). With a median follow-up of 50 months (IQR 38-61), disease-free survival at 3 years was 75·9% (95% CI 72·4-79·5) in the investigational group and 71·2% (95% CI 67·6-74·9) in the control group (hazard ratio [HR] 0·79, 95% CI 0·64-0·98; p=0·03). Preoperative grade 3-4 toxic effects occurred in 144 (24%) of 607 patients who actually received fluorouracil and oxaliplatin during chemoradiotherapy and in 128 (20%) of 625 patients who actually received fluorouracil chemoradiotherapy. Of 445 patients who actually received adjuvant fluorouracil and leucovorin and oxaliplatin, 158 (36%) had grade 3-4 toxic effects, as did 170 (36%) of 470 patients who actually received adjuvant fluorouracil. Late grade 3-4 adverse events in patients who received protocol-specified preoperative and postoperative treatment occurred in 112 (25%) of 445 patients in the investigational group, and in 100 (21%) of 470 patients in the control group.Adding oxaliplatin to fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy (at the doses and intensities used in this trial) significantly improved disease-free survival of patients with clinically staged cT3-4 or cN1-2 rectal cancer compared with our former fluorouracil-based combined modality regimen (based on CAO/ARO/AIO-94). The regimen established by CAO/ARO/AIO-04 can be deemed a new treatment option for patients with locally advanced rectal cancer.German Cancer Aid (Deutsche Krebshilfe).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
落后从阳完成签到 ,获得积分10
1分钟前
2分钟前
瓜皮糖浆发布了新的文献求助30
2分钟前
港港完成签到 ,获得积分10
2分钟前
2分钟前
瓜皮糖浆完成签到,获得积分10
2分钟前
浅黑色饕餮完成签到,获得积分10
2分钟前
斯文败类应助浅黑色饕餮采纳,获得10
2分钟前
拜托你清醒一点完成签到 ,获得积分10
3分钟前
lelecha发布了新的文献求助10
3分钟前
3分钟前
zs完成签到 ,获得积分10
3分钟前
lelecha完成签到,获得积分10
3分钟前
4分钟前
风起云涌龙完成签到 ,获得积分0
4分钟前
bkagyin应助科研通管家采纳,获得10
5分钟前
mellow发布了新的文献求助10
5分钟前
Aloha完成签到 ,获得积分10
6分钟前
熊一只发布了新的文献求助10
6分钟前
nanfang完成签到 ,获得积分10
7分钟前
光亮的自行车完成签到 ,获得积分10
7分钟前
Qvby3完成签到 ,获得积分10
7分钟前
领导范儿应助科研通管家采纳,获得10
7分钟前
可爱的函函应助Jenaloe采纳,获得10
7分钟前
7分钟前
8分钟前
8分钟前
Jenaloe发布了新的文献求助10
8分钟前
Jenaloe完成签到,获得积分10
8分钟前
8分钟前
落后的西牛完成签到 ,获得积分10
8分钟前
Artin完成签到,获得积分10
9分钟前
深情安青应助科研通管家采纳,获得10
9分钟前
xzn发布了新的文献求助10
10分钟前
Rebeccaiscute完成签到 ,获得积分10
10分钟前
WANG发布了新的文献求助10
10分钟前
小王完成签到 ,获得积分10
11分钟前
12分钟前
林夏果发布了新的文献求助10
12分钟前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
Introduction to Modern Controls, with illustrations in MATLAB and Python 310
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3056457
求助须知:如何正确求助?哪些是违规求助? 2713069
关于积分的说明 7434540
捐赠科研通 2358102
什么是DOI,文献DOI怎么找? 1249268
科研通“疑难数据库(出版商)”最低求助积分说明 607010
版权声明 596195